Loading...
•
Dec 31, 2019
Tandem Diabetes Q4 2019 Earnings Report
Tandem Diabetes' financial results for Q4 2019 and full year 2019 were announced.
Key Takeaways
Tandem Diabetes Care reported a 42% increase in sales for the fourth quarter of 2019, reaching $108.4 million, and a net income of $2.7 million. The company's worldwide pump shipments increased by 21% compared to the same period in 2018. They are guiding for sales between $450 million and $465 million for the year ending December 31, 2020.
Worldwide pump shipments increased 21% to 19,602 pumps.
Sales increased 42% to $108.4 million.
Gross margin improved 1 point to 56% of sales.
Adjusted EBITDA improved to 21% of sales.
Revenue by Geographic Location
Forward Guidance
For the year ending December 31, 2020, the Company is providing its financial guidance as follows:
Positive Outlook
- Sales are estimated to be in the range of $450 million to $465 million, which represents an annual sales growth of 24 percent to 28 percent compared to 2019
- Includes international sales of approximately $70 million to $75 million
- Gross margin is estimated to be approximately 54 percent
- Adjusted EBITDA is estimated to be 12 percent to 14 percent
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $60 million
Challenges Ahead
- Approximately $50 million in non-cash, stock-based compensation expense
- Approximately $10 million of depreciation and amortization
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...